Therapeutic Potential of Curcumin in Reversing the Depression and Associated Pseudodementia via Modulating Stress Hormone, Hippocampal Neurotransmitters, and BDNF Levels in Rats

Afzal, Asia; Batool, Zehra; Sadir, Sadia; Liaquat, Laraib; Shahzad, Sidrah; Tabassum, Saiqa; Ahmad, Saara; Kamil, Noor; Perveen, Tahira; Haider, Saida

doi:10.1007/s11064-021-03430-x

Cited by 21 publications

(17 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty studies reported an increment of 5-HT levels in the hippocampus, striatum or frontal cortex, which may be due to the interaction found between curcumin and 5-HT/cAMP/PKA/CREB/BDNF-signaling pathway or 5-HT 1A/1B and 5-HT 2C receptors [ 35 , 40 , 80 , 83 , 85 , 90 ]. Besides, fifteen studies reported an increased level of DA [ 38 , 41 , 42 , 44 , 45 , 46 , 48 , 49 , 55 , 72 , 77 , 81 , 87 , 91 ]. NA was also incremented in five studies [ 46 , 49 , 55 , 63 , 86 ].…”

Section: Resultsmentioning

confidence: 99%

“…NA was also incremented in five studies [ 46 , 49 , 55 , 63 , 86 ]. In addition, curcumin has been claimed to present beneficial effects on reducing inflammatory cytokines (IL-1β, IL-6) [ 60 , 63 , 69 , 70 , 71 , 76 , 77 , 91 ], reducing the NF-κB-iNOS-COX-2-TNF-α inflammatory signaling pathway [ 39 , 51 , 52 ], and modulating the levels of antioxidant markers, such as monoamine oxidase (MAO), malondialdehyde (MDA), CAT, or SOD [ 43 , 56 , 57 , 62 , 65 , 66 , 82 , 84 , 88 ]. Furthermore, the BDNF is incremented by curcumin treatment [ 36 , 39 , 47 , 51 , 54 , 58 , 66 , 67 , 77 , 78 , 90 ].…”

Section: Resultsmentioning

confidence: 99%

“…In addition, curcumin has been claimed to present beneficial effects on reducing inflammatory cytokines (IL-1β, IL-6) [ 60 , 63 , 69 , 70 , 71 , 76 , 77 , 91 ], reducing the NF-κB-iNOS-COX-2-TNF-α inflammatory signaling pathway [ 39 , 51 , 52 ], and modulating the levels of antioxidant markers, such as monoamine oxidase (MAO), malondialdehyde (MDA), CAT, or SOD [ 43 , 56 , 57 , 62 , 65 , 66 , 82 , 84 , 88 ]. Furthermore, the BDNF is incremented by curcumin treatment [ 36 , 39 , 47 , 51 , 54 , 58 , 66 , 67 , 77 , 78 , 90 ]. Other effects of curcumin have been described in different animal models of depression, such as an interaction with glutamate N-Methyl-D-Aspartate (NMDA) receptors [ 37 ], an inhibition of Ca +2 channels [ 74 ], an increased level of corticosterol and cortisone in plasma [ 64 ], or an altered lipid metabolism [ 75 ], or an upregulation of the insulin receptor IRS-1 and protein kinase-B (PKB) in the liver [ 73 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There have been several animal trials that have confirmed curcumin can lower corticosterone concentrations in mice and rats exposed to various animal stress and depression models. These include after chronic exposure to restraint stress [ 23 ], social defeat stress [ 22 ], unpredictable mild stress [ 14 ], and exposure to mercury chloride [ 49 ]. Corticosterone-lowering effects from curcumin may occur via its ability to inhibit adrenocorticotropic hormone secretion [ 111 ], its influence on 11β-hydroxysteroid dehydrogenase activity (an enzyme involved in the interconversion of cortisol and cortisone) [ 112 – 114 ] and/or glucocorticoid receptor sensitivity and expression in the brain [ 26 , 115 ].…”

Section: Curcumin’s Potential Antidepressant Mechanisms Of Actionmentioning

confidence: 99%

“…This theory is supported by findings of lowered concentrations of serum and plasma BDNF in patients with depression and the ability of many pharmaceutical antidepressants to increase BDNF concentrations [ 127 , 128 ]. Results from animal stress models have confirmed curcumin can increase concentrations of BDNF [ 23 , 29 , 34 , 129 , 130 ]. Increases in peripheral BDNF have also been identified in several human trials.…”

Section: Curcumin’s Potential Antidepressant Mechanisms Of Actionmentioning

confidence: 99%

Potential Role of Curcumin for the Treatment of Major Depressive Disorder

Lopresti

2022

CNS Drugs

View full text Add to dashboard Cite

Curcumin is the major biologically active polyphenolic constituent in the turmeric plant (Curcuma longa) that has been shown to have antioxidant, anti-inflammatory, neuroprotective, anticancer, antimicrobial, and cardioprotective effects. Interest in curcumin as a treatment for mental health conditions has increased and there is an expanding body of preclinical and clinical research examining its antidepressant and anxiolytic effects. In this narrative review, human trials investigating the effects of curcumin for the treatment of depression or depressive symptoms are summarised. Using findings from in vitro, animal, and human trials, possible biological mechanisms associated with the antidepressant effects of curcumin are also explored. To increase the understanding of curcumin for the treatment of depression, directions for future research are proposed. Key PointsEvidence from animal and human trials confirms curcumin is a promising treatment for depression.Curcumin has multiple biological actions that may account for its antidepressant effects.More research is required to increase the understanding of the antidepressant effects of curcumin.

show abstract